Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 35,000 shares at $14.84 ($525K) on 2023-06-21, disclosed to the SEC on 2023-06-23.
Scheduled sale ($525k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.84 | 8,593 | $128K | 24.3% |
| 2 | $14.84 | 8,593 | $128K | 24.3% |
| 3 | $15.17 | 8,907 | $135K | 25.7% |
| 4 | $15.17 | 8,907 | $135K | 25.7% |
| Total | $15.01 avg | 35,000 | $525K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |